Design and synthesis of new secretory phospholipase A2 inhibitor of a phospholipid analog. 1998

S Iwama, and M Segawa, and S Fujii, and K Ikeda, and S Katsumura
School of Science, Kwansei Gakuin University, Nishinomiya, Japan.

All stereoisomers of N-acyl-4,5-disubstituted oxazolidinone phospholipid analogs were synthesized by regio and stereoselective epoxide ring opening accompanied by introduction of an amino group. The (4R,5S)-derivative showed stronger inhibitory activity toward type II phospholipase A2 than the 4-substituted oxazolidinone phospholipid analog previously reported.

UI MeSH Term Description Entries
D010741 Phospholipases A Phospholipases that hydrolyze one of the acyl groups of phosphoglycerides or glycerophosphatidates.
D010743 Phospholipids Lipids containing one or more phosphate groups, particularly those derived from either glycerol (phosphoglycerides see GLYCEROPHOSPHOLIPIDS) or sphingosine (SPHINGOLIPIDS). They are polar lipids that are of great importance for the structure and function of cell membranes and are the most abundant of membrane lipids, although not stored in large amounts in the system. Phosphatides,Phospholipid
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D013237 Stereoisomerism The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Molecular Stereochemistry,Stereoisomers,Stereochemistry, Molecular,Stereoisomer
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D054467 Phospholipases A2 Phospholipases that hydrolyze the acyl group attached to the 2-position of PHOSPHOGLYCERIDES. Lecithinase A2,Phospholipase A2

Related Publications

S Iwama, and M Segawa, and S Fujii, and K Ikeda, and S Katsumura
October 1995, Bioorganic & medicinal chemistry,
S Iwama, and M Segawa, and S Fujii, and K Ikeda, and S Katsumura
January 1995, Journal of biochemistry,
S Iwama, and M Segawa, and S Fujii, and K Ikeda, and S Katsumura
August 2004, Biological & pharmaceutical bulletin,
S Iwama, and M Segawa, and S Fujii, and K Ikeda, and S Katsumura
April 2002, The Journal of biological chemistry,
S Iwama, and M Segawa, and S Fujii, and K Ikeda, and S Katsumura
July 2020, ACS nano,
S Iwama, and M Segawa, and S Fujii, and K Ikeda, and S Katsumura
July 1989, Journal of cellular biochemistry,
S Iwama, and M Segawa, and S Fujii, and K Ikeda, and S Katsumura
February 2010, Inflammopharmacology,
S Iwama, and M Segawa, and S Fujii, and K Ikeda, and S Katsumura
January 2011, Chemico-biological interactions,
S Iwama, and M Segawa, and S Fujii, and K Ikeda, and S Katsumura
June 2011, Langmuir : the ACS journal of surfaces and colloids,
S Iwama, and M Segawa, and S Fujii, and K Ikeda, and S Katsumura
April 1985, Biochemical and biophysical research communications,
Copied contents to your clipboard!